These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36031544)

  • 1. siRNA modification and delivery for drug development.
    Zhang M; Huang Y
    Trends Mol Med; 2022 Oct; 28(10):892-893. PubMed ID: 36031544
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chitosan-siRNA complex nanoparticles for gene silencing].
    Liu X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Feb; 27(1):97-101. PubMed ID: 20337033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioengineered nanoparticles for siRNA delivery.
    Kozielski KL; Tzeng SY; Green JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):449-68. PubMed ID: 23821336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycation-based nanoparticle delivery for improved RNA interference therapeutics.
    Howard KA; Kjems J
    Expert Opin Biol Ther; 2007 Dec; 7(12):1811-22. PubMed ID: 18034647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced delivery of monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly l-lysine nanoparticles loading platelet-derived growth factor BB small interfering RNA by ultrasound and/or microbubbles to rat retinal pigment epithelium cells.
    Du J; Shi QS; Sun Y; Liu PF; Zhu MJ; Du LF; Duan YR
    J Gene Med; 2011 Jun; 13(6):312-23. PubMed ID: 21674734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SiRNA drug delivery by biodegradable polymeric nanoparticles.
    Yuan X; Li L; Rathinavelu A; Hao J; Narasimhan M; He M; Heitlage V; Tam L; Viqar S; Salehi M
    J Nanosci Nanotechnol; 2006; 6(9-10):2821-8. PubMed ID: 17048488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of small RNA using lipid nanoparticles.
    Asai T; Oku N
    Biol Pharm Bull; 2014; 37(2):201-5. PubMed ID: 24492716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.
    Zhong J; Huang HL; Li J; Qian FC; Li LQ; Niu PP; Dai LC
    Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):82-9. PubMed ID: 25655295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
    Lu ZR; Laney VEA; Hall R; Ayat N
    Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA interference technology with emphasis on delivery vehicles-prospects and limitations.
    Prabha S; Vyas R; Gupta N; Ahmed B; Chandra R; Nimesh S
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1391-9. PubMed ID: 26140615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles.
    Lee J; Yun KS; Choi CS; Shin SH; Ban HS; Rhim T; Lee SK; Lee KY
    Bioconjug Chem; 2012 Jun; 23(6):1174-80. PubMed ID: 22607555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
    Gangopadhyay S; Nikam RR; Gore KR
    Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.